The purpose is to determine if this microdose can improve core ADHD symptoms, help with emotional regulation, and enhance sleep.

Participants will receive either the study drug or the placebo each day for a set number of weeks. Throughout the trial, they will attend regular visits where simple questionnaires about attention, mood, and sleep are completed, and a brief blood sample is taken to assess the activity of the enzyme CYP2D6, which helps the body process medicines. Safety checks and brief assessments are performed to monitor any effects.

Participants in the study will include adults diagnosed with ADHD, both those who have mood disorders and those who do not, as well as a group of healthy individuals without any psychiatric or neurological history. The study will involve using advanced imaging techniques like EEG (electroencephalogram) and MRI (magnetic resonance imaging) to observe changes in brain activity. These techniques help researchers see how the brain responds to tasks and rest periods, and how methylphenidate might alter these responses.

The study will take place over a period of time, during which participants will receive either methylphenidate or a placebo. Researchers will measure various outcomes, such as changes in brain blood flow and cognitive performance, to determine the impact of the medication. The goal is to better understand how methylphenidate affects brain function in people with ADHD and mood disorders, which could lead to improved treatment strategies in the future.

The purpose of the study is to understand how Ritalin and its active component, known as alpha-phenyl 2-piperidine acid, behave in the body over time. Participants will be given Ritalin in the form of a prolonged-release capsule, which means the medication is released slowly into the body. The study will involve taking blood samples at various times after taking the medication to measure how much of the drug and its active component are present in the bloodstream. This will help researchers see if there are differences between those with and without obesity.

Throughout the study, participants will also be asked about how effective they feel Ritalin is in managing their ADHD symptoms, such as attention and hyperactivity. This feedback will be collected using a simple scale. The study will also gather some basic information about participants, like age, weight, and lifestyle habits, to help understand the results better. The study is expected to continue until March 2026.

Participants in the study will be randomly assigned to receive either melatonin, quetiapine, or a placebo. The treatment will be given in the form of film-coated tablets, which are taken orally. The study will last for a period of six months, during which the effects of the treatments on sleep and overall well-being will be monitored. The study aims to provide insights into which treatment might be more effective in managing insomnia in adolescents with psychiatric conditions.

Throughout the study, various aspects of the participants’ sleep and mental health will be assessed. This includes measuring the severity of insomnia using the Insomnia Severity Index, evaluating sleep quality, and assessing psychosocial functioning and subjective well-being. The study will also look at how the treatments affect rest-sleep-activity cycles and other physiological variables. The findings from this study could help improve treatment options for young people dealing with both psychiatric disorders and sleep difficulties.

The purpose of the study is to assess the occurrence of any side effects in those taking the active medications compared to those taking the placebo. The study will take place over several visits, where participants will be monitored for any changes in their condition and any side effects they might experience. The study will last for a maximum of 12 weeks, during which participants will be asked to take the medication or placebo daily.

Throughout the study, participants will have regular check-ups to monitor their health and any changes in their symptoms. The goal is to gather information on how well the medications work and how safe they are for people with both ADHD and depression. This information will help in understanding the potential benefits and risks of using dexamfetamine sulfate for treating these conditions together.

Participants in the study will receive both medications at different times, allowing researchers to compare their effects. The study will last for a total of six months, during which participants will take one medication for a period and then switch to the other. Throughout the study, participants will be monitored for changes in ADHD symptoms, as well as any effects on their diabetes, such as blood sugar levels. The study will also track any side effects that may occur while taking these medications.

The goal is to determine which medication is more effective in managing ADHD symptoms while also considering the impact on diabetes control. This information will help doctors make better treatment decisions for children and teenagers who have both ADHD and Type 1 Diabetes. Participants will be closely observed by healthcare professionals to ensure their safety and well-being throughout the study.

Participants in the study will be randomly assigned to receive either the immediate-release tablets, the modified-release capsules, or a placebo. The study will be conducted in a way that neither the participants nor the researchers know which treatment is being given, ensuring unbiased results. The trial will last for a period of 44 weeks, during which participants will take the medication orally. The study aims to observe changes in ADHD symptoms over time and assess any side effects that may occur.

The trial will involve regular visits to monitor the participants’ progress and gather data on the effectiveness of the treatments. By the end of the study, researchers hope to gain valuable insights into the potential benefits of using dexamfetamine sulfate formulations for treating ADHD in adults. This information could help improve treatment options for individuals living with this condition.

The trial will compare Guanfacine Hydrochloride with another medication called Atomoxetine Hydrochloride, which is also used to treat ADHD. Participants will be randomly assigned to receive either Guanfacine Hydrochloride, Atomoxetine Hydrochloride, or a placebo. The study will begin with a phase where the best dose for each participant is determined, followed by a period where the medication is taken regularly. The trial will last for a total of 12 months, during which the participants’ attention and reaction times will be monitored using a computer-based test called the Cambridge Automated Neuropsychological Test Battery (CANTAB).

The main goal of the study is to evaluate the long-term safety of Guanfacine Hydrochloride and its effects on attention and psychomotor speed, which refers to the coordination between thinking and physical movement. The study will also look at other health indicators such as weight, height, and vital signs like blood pressure and heart rate. This research aims to provide valuable information on the use of Guanfacine Hydrochloride for managing ADHD in children and adolescents.